sorafenib has been researched along with Cancer of Gallbladder in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
| Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB | 1 |
| Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S | 1 |
| Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S | 1 |
| Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ | 1 |
| Faris, JE; Zhu, AX | 1 |
1 review(s) available for sorafenib and Cancer of Gallbladder
| Article | Year |
|---|---|
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
5 trial(s) available for sorafenib and Cancer of Gallbladder
| Article | Year |
|---|---|
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2014 |
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib | 2010 |
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Disease-Free Survival; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |